Gagal Hepar

01Pathophysiology

Liver failure occurs when the liver loses its ability to perform its core functions: synthesis, detoxification, and excretion. This can happen acutely in a previously healthy liver or as the end result of progressive chronic liver disease. Understanding these two pathways is essential because exam questions will test whether you can differentiate them.

In acute liver failure (ALF), the fundamental event is widespread hepatocyte necrosis or apoptosis occurring over days to weeks. The trigger, whether it is a toxin like acetaminophen, a virus, or an ischemic insult, initiates a cascade of cell death that overwhelms the liver's regenerative capacity. The result is a simultaneous collapse of multiple hepatic functions. Synthetic function fails first and most visibly: the liver can no longer produce clotting factors (especially factors II, V, VII, IX, and X), leading to coagulopathy reflected by a rising INR. Factor V is particularly important because it is not vitamin K-dependent, so a low factor V level in the setting of liver failure confirms that the coagulopathy is from hepatocellular damage rather than from vitamin K deficiency or cholestasis.

The loss of detoxification capacity is what produces hepatic encephalopathy. Ammonia, normally converted to urea via the urea cycle in hepatocytes, accumulates in the blood. It crosses the blood-brain barrier, where astrocytes convert it to glutamine. The osmotic load from glutamine accumulation within astrocytes causes cerebral edema, which is the leading cause of death in acute liver failure. This explains why encephalopathy in ALF is far more dangerous than in chronic liver disease: in chronic failure, compensatory mechanisms (increased astrocyte glutamine efflux, cerebral adaptation) partially protect against edema.

The liver also fails to maintain glucose homeostasis. Normally, the liver stores glycogen and performs gluconeogenesis. When hepatocytes are destroyed, both processes stop, leading to hypoglycemia, a common and dangerous complication that must be monitored continuously.

In chronic liver failure, the pathophysiology is driven by progressive fibrosis and cirrhosis. Repeated injury from alcohol, chronic hepatitis, or metabolic disease triggers hepatic stellate cell activation. These cells deposit collagen in the space of Disse, distorting the normal sinusoidal architecture. Over months to years, this fibrosis leads to portal hypertension, as blood flow through the scarred liver encounters increasing resistance. Portal hypertension is the central mechanism behind most complications of chronic liver failure: varices form as portosystemic collaterals develop, ascites accumulates due to splanchnic vasodilation and sodium retention, and splenomegaly with resulting hypersplenism and thrombocytopenia develops.

The hepatorenal syndrome seen in advanced cirrhosis results from extreme splanchnic vasodilation causing renal vasoconstriction as the body tries to maintain systemic blood pressure. This is a functional renal failure, not structural kidney damage, and it is reversible with liver transplantation.

02Classification and Clinical Manifestation

Acute Liver Failure Classification by Onset

West Haven Criteria for Hepatic Encephalopathy

Child-Pugh Classification (Chronic Liver Failure / Cirrhosis Severity)

03Diagnostic Workup

The best initial test when liver failure is suspected is a combination of serum aminotransferases (AST and ALT) and the PT/INR. The INR is the single most important laboratory value for defining and monitoring acute liver failure because it directly reflects the liver's ability to synthesize clotting factors with short half-lives (factor VII has a half-life of only about 6 hours). A rising INR in the setting of liver injury is an ominous sign that indicates worsening hepatocellular function. Albumin, by contrast, has a much longer half-life (approximately 20 days), so it remains normal early in acute liver failure and is more useful as a marker of chronic liver disease severity.

An acetaminophen level must be obtained in every patient presenting with acute liver failure, even if the patient denies ingestion, because acetaminophen is the most common cause and has a readily available antidote. The Rumack-Matthew nomogram can guide treatment decisions when the time of ingestion is known, but in cases of acute liver failure with unknown ingestion timing, NAC should be started empirically without waiting for the level.

A complete viral hepatitis panel is essential. Do not limit testing to hepatitis B and C. Hepatitis A and E can both cause acute liver failure, and IgM-class antibodies confirm acute infection. In young patients (generally under 40), Wilson disease must always be excluded because it is one of the few causes of ALF that does not respond to supportive care alone and requires urgent transplant evaluation. A low ceruloplasmin, high urine copper, and the presence of Kayser-Fleischer rings on slit-lamp examination point to Wilson disease. A useful clue on the exam is Wilson disease presenting with ALF plus Coombs-negative hemolytic anemia.

The most accurate test for determining etiology is liver biopsy, but this is rarely performed in acute liver failure because of the severe coagulopathy. When biopsy is absolutely necessary, a transjugular approach is used to minimize bleeding risk. In chronic liver failure, non-invasive alternatives such as transient elastography (FibroScan) and the FIB-4 index ($FIB\text{-}4=\frac{Age\times AST}{PlateletCount\times \sqrt{ALT}}FIB\backslash text\{-\}4\; =\; \backslash frac\{Age\; \backslash times\; AST\}\{Platelet\backslash \; Count\; \backslash times\; \backslash sqrt\{ALT\}\}$) are increasingly used to estimate fibrosis without biopsy.

Doppler ultrasonography of the hepatic vessels is obtained early to rule out Budd-Chiari syndrome (thrombosis of the hepatic veins), which presents with the classic triad of ascites, hepatomegaly, and abdominal pain and can cause acute liver failure.

04Management and Treatment

Acute stabilization in liver failure begins with identifying and treating the cause. For acetaminophen toxicity, NAC is the cornerstone and should be started immediately whenever suspicion exists, even before the level returns. NAC works as a glutathione precursor, replenishing the hepatocyte's primary defense against the toxic metabolite NAPQI. In non-acetaminophen acute liver failure, NAC has also been shown to improve transplant-free survival in patients with early (Grade I-II) encephalopathy and should be administered as a 72-hour IV infusion.

Hepatic encephalopathy is managed with lactulose as the first-line agent. Lactulose works through two mechanisms: it is metabolized by colonic bacteria into organic acids that lower the pH, converting ammonia ($N{H}_{3}NH\_3$) to ammonium ($N{H}_4^{+}NH\_4^+$) which cannot be absorbed, and it acts as an osmotic laxative to increase fecal nitrogen excretion. The dose is titrated to produce 2 to 3 soft bowel movements per day. Rifaximin is added as an adjunct, particularly for secondary prevention of recurrent encephalopathy episodes. It reduces ammonia-producing gut flora without systemic absorption.

A critical teaching point: do not correct coagulopathy with FFP unless the patient is actively bleeding or requires an invasive procedure. The INR is one of the most important prognostic indicators in acute liver failure, and giving FFP "normalizes" the number without changing the underlying liver function. This makes it impossible to track disease progression or determine transplant eligibility. This concept is frequently tested.

Cerebral edema requires aggressive management with mannitol (osmotic diuresis to reduce intracranial pressure) or hypertonic saline (to draw fluid out of the edematous brain). Patients with Grade III-IV encephalopathy should be intubated for airway protection and monitored in an intensive care setting. Head-of-bed elevation to 30 degrees and avoidance of stimulation are standard supportive measures.

Long-term management depends on whether the patient recovers or progresses to needing transplantation. Patients with chronic liver failure (decompensated cirrhosis) require ongoing management of complications: diuretics for ascites (spironolactone 100 mg daily as first-line, often combined with furosemide 40 mg daily in a 100:40 ratio), non-selective beta-blockers (propranolol or carvedilol) for portal hypertension and variceal bleeding prophylaxis, and regular surveillance for hepatocellular carcinoma (ultrasound with or without alpha-fetoprotein every 6 months). The MELD score ($MELD=3.78\times \ln [bilirubin]+11.2\times \ln [INR]+9.57\times \ln [creatinine]+6.43MELD\; =\; 3.78\; \backslash times\; \backslash ln[bilirubin]\; +\; 11.2\; \backslash times\; \backslash ln[INR]\; +\; 9.57\; \backslash times\; \backslash ln[creatinine]\; +\; 6.43$) is used to prioritize patients on the transplant waiting list.

Contraindications and cautions: Sedatives and benzodiazepines must be avoided because they are metabolized by the liver and can precipitate or worsen encephalopathy. NSAIDs are contraindicated due to renal effects and bleeding risk. Aminoglycosides should be avoided given the risk of hepatorenal syndrome.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on liver failure questions is by correcting the INR with FFP in the absence of active bleeding. This is the single highest-yield trap. The vignette will describe a patient with acute liver failure and an INR of 4.0 or higher, and an answer choice will offer FFP. The instinct is to "fix the number," but the correct approach is to leave the INR alone because it is the most sensitive real-time marker of liver function and drives transplant decision-making. Giving FFP obscures the clinical trajectory and offers no benefit unless the patient is bleeding or needs a procedure.

A second common mistake is failing to start NAC when the cause of acute liver failure is unknown. Students may hesitate to give NAC when the acetaminophen level is not back or the cause is unclear. The correct answer is to begin NAC empirically in virtually all cases of acute liver failure while the workup is pending. There is evidence of benefit even in non-acetaminophen causes when encephalopathy is early stage.

The third trap involves Wilson disease. When a young patient (under 40) presents with fulminant liver failure and Coombs-negative hemolytic anemia, Wilson disease must be at the top of the differential. A paradoxically low alkaline phosphatase in the setting of high bilirubin is a strong discriminator that students frequently overlook.

Finally, students confuse acute liver failure with decompensated cirrhosis. The distinction matters because the definition of acute liver failure requires the absence of pre-existing liver disease. If the vignette describes spider angiomata, palmar erythema, a small nodular liver, or thrombocytopenia from hypersplenism, the patient has chronic disease that has decompensated, not acute liver failure. The management priorities, prognosis, and transplant criteria differ between these two entities, and exam questions are designed to test whether you can tell them apart.

The core competency being tested across liver failure questions is the ability to recognize the syndrome (coagulopathy plus encephalopathy), identify the etiology through systematic workup, and make the correct management decisions, particularly knowing what not to do (do not sedate, do not correct INR without indication, do not delay NAC).